Paid Clinical Trials Kentucky
Discover 954 paid clinical trials in Kentucky. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies
Sponsor:
Ellipses Pharma
Location:
Code:
NCT05443126
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
EP0031
Remote Alcohol Monitoring to Facilitate Abstinence From Alcohol: Exp 1Remote Alcohol Monitoring to Facilitate Abstinence From Alcohol: Exp 1
Sponsor:
Mikhail N Koffarnus
Location:
Code:
NCT03883126
Conditions
Alcohol Use Disorder
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Contingency management
Life's End Benefits of CannaBidiol and TetrahYdrocannabinolLife's End Benefits of CannaBidiol and TetrahYdrocannabinol
Sponsor:
University of Southern California
Location:
Code:
NCT05644262
Conditions
Agitation
Dementia
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
T2:C100
Placebo
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Sponsor:
Chimerix
Location:
Code:
NCT05580562
Conditions
H3 K27M
Glioma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Dordaviprone (ONC201)
Dordaviprone (ONC201) + Placebo
Placebo
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Sponsor:
Iovance Biotherapeutics, Inc.
Location:
Code:
NCT05361174
Conditions
Unresectable Melanoma
Metastatic Melanoma
Stage III Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
IOV-4001
Cortical Organization in Allogeneic Transplants or Heterotopic Hand ReplantsCortical Organization in Allogeneic Transplants or Heterotopic Hand Replants
Sponsor:
Christine M. Kleinert Institute for Hand and Microsurgery
Location:
Code:
NCT01618682
Conditions
Hand Transplant
Hand Replant
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Sponsor:
Qurient Co., Ltd.
Location:
Code:
NCT05438420
Conditions
Esophageal Cancer
Gastric Cancer
Hepatocellular Cancer
Cervical Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Q702
Pembrolizumab
A Research Study to Advance the CF Therapeutics Pipeline for People Without ModulatorsA Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Sponsor:
Nicole Hamblett
Location:
Code:
NCT06504589
Conditions
Cystic Fibrosis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression